Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Larkin

Showing results (1-10 of 418) with videos related to

Pageof 42
Sort By:
Future Healthcare Journal|July 22, 2025
The FHJ debate: The General Medical Council (GMC) should support a mandatory register of interests for UK doctorsJames Larkin
World Journal of Urology|January 9, 2013
Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistanceMuhammad Khattak, James Larkin
The Lancet. Oncology|November 12, 2013
Axitinib in advanced renal-cell carcinomaNadia Yousaf, James Larkin
Immunotherapy|May 21, 2016
Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanomaLavinia Spain, James Larkin
European Journal of Cancer (Oxford, England : 1990)|November 10, 2016
Systemic treatment of advanced papillary renal cell carcinoma: Where next?Samra Turajlic, James Larkin
Expert Opinion on Drug Safety|July 7, 2017
The safety of nivolumab for the treatment of metastatic melanomaAine O'Reilly, James Larkin
The Lancet. Oncology|December 19, 2015
Precision oncology: where next?Martin Gore, James Larkin
The New England Journal of Medicine|August 23, 2018
Immunotherapy for Melanoma Metastatic to the BrainSamra Turajlic, James Larkin
Cancer Management and Research|August 21, 2012
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaRosalie Fisher, James Larkin
Clinical Genitourinary Cancer|December 5, 2025
Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid UseTobias Peres, James Larkin
Pageof 42

Showing results (1-10 of 418) with videos related to

Sort By:
Pageof 42
Future Healthcare Journal|July 22, 2025
The FHJ debate: The General Medical Council (GMC) should support a mandatory register of interests for UK doctorsJames Larkin
World Journal of Urology|January 9, 2013
Sequential therapy with targeted agents in metastatic renal cell carcinoma: beyond second-line and overcoming drug resistanceMuhammad Khattak, James Larkin
The Lancet. Oncology|November 12, 2013
Axitinib in advanced renal-cell carcinomaNadia Yousaf, James Larkin
Immunotherapy|May 21, 2016
Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanomaLavinia Spain, James Larkin
European Journal of Cancer (Oxford, England : 1990)|November 10, 2016
Systemic treatment of advanced papillary renal cell carcinoma: Where next?Samra Turajlic, James Larkin
Expert Opinion on Drug Safety|July 7, 2017
The safety of nivolumab for the treatment of metastatic melanomaAine O'Reilly, James Larkin
The Lancet. Oncology|December 19, 2015
Precision oncology: where next?Martin Gore, James Larkin
The New England Journal of Medicine|August 23, 2018
Immunotherapy for Melanoma Metastatic to the BrainSamra Turajlic, James Larkin
Cancer Management and Research|August 21, 2012
Vemurafenib: a new treatment for BRAF-V600 mutated advanced melanomaRosalie Fisher, James Larkin
Clinical Genitourinary Cancer|December 5, 2025
Ipilimumab and Nivolumab in Renal Cell Carcinoma: Real-World Experience in Rare Variant Renal Cell Carcinoma, Brain Metastases and Impact of Immune-Related Adverse Events and Steroid UseTobias Peres, James Larkin
Pageof 42